Stephen John Palmer

Search results

• 2015

  The value of implementation: how to invest in getting cost-effective technologies into practice. Framework and application to novel oral anticoagulants in the prevention of stroke and systemic embolism

  Faria, R., Walker, S. M., Whyte, S., Dixon, S., Palmer, S. J. & Sculpher, M., 2015, (Unpublished).

  Research output: Working paper

• 2011

  Uncertainty, evidence and irrecoverable costs: informing approval, pricing and research decisions for health technologies

  Claxton, K. P., Palmer, S. J., Longworth, L., Bojke, L., Griffin, S., McKenna, C., Soares, M. O., Spackman, E. & Youn, J., Oct 2011, York, UK: Centre for Health Economics, University of York, 81 p. (CHE Research Paper; no. 69).

  Research output: Working paper

  Open Access

  File
• 2009

  The use of paclitaxel in the management of early stage breast cancer.

  Griffin, S., Dunn, G., Palmer, S., Macfarlane, S., Brent, S., Dyker, A., Erhorn, A., Humphries, C., White, S., Horsley, W., Ferrie, L. & Thomas, S., 2009.

  Research output: Working paper

• 2006

  Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (update): a systematic review and economic evaulation

  Main, C., Ginnelly, L., Griffin, S., Norman, G., Barbieri, M., Mather, L., Stark, D., Palmer, S. & Riemsma, R., 2006.

  Research output: Working paper

• 2004

  Building a reference case for Bayesian applications to health economics and outcome research

  Claxton, K., Fenwick, E., Palmer, S., Sculpher, M., Abrams, K. & Sutton, A., 2004, (CHE Technical Paper Series).

  Research output: Working paper